Citi downgraded SanBio to Sell from Neutral with a price target of 1,100 yen, up from 500 yen, following the announcement of conditional regulatory approval for Akuugo. The firm now assumes that Akuugo will begin shipping in Feb-Apr 2025, previously 2026, following resolution of manufacturing issues. Citi assumes peak annual sales of 36B yen, as the requirement that all cases be surveyed for the time being limits the number of medical institutions that can use the drug and SanBio’s sales capabilities are also limited.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNBIF: